Výsledky vyhledávání - Langmuir, Peter

JAK inhibitors and COVID-19 Autor Levy, Gabriel, Guglielmelli, Paola, Langmuir, Peter, Constantinescu, Stefan N

Získat plný text Získat plný text Získat plný text

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm Autor Langmuir, Peter, Yeleswaram, Swamy, Smith, Paul, Knorr, Barbara, Squier, Peg

Získat plný text Získat plný text Získat plný text

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment Autor Yeleswaram, Swamy, Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter

Získat plný text Získat plný text Získat plný text

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance Autor Kishimoto, Koji, Sandner, Sigrid, Imitola, Jaime, Sho, Masayuki, Li, Yongsheng, Langmuir, Peter B., Rothstein, David M., Strom, Terry B., Turka, Laurence A., Sayegh, Mohamed H.

Získat plný text Získat plný text Získat plný text

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer Autor Hanrahan, Emer O., Lin, Heather Y., Kim, Edward S., Yan, Shaoyu, Du, Danny Z., McKee, Kathryn S., Tran, Hai T., Lee, J. Jack, Ryan, Anderson J., Langmuir, Peter, Johnson, Bruce E., Heymach, John V.

Získat plný text Získat plný text Získat plný text

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses Autor Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

Získat plný text Získat plný text Získat plný text

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial Autor Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.

Získat plný text Získat plný text Získat plný text

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Autor Herbst, Roy S, Sun, Yan, Eberhardt, Wilfried E E, Germonpré, Paul, Saijo, Nagahiro, Zhou, Caicun, Wang, Jie, Li, Longyun, Kabbinavar, Fairooz, Ichinose, Yukito, Qin, Shukui, Zhang, Li, Biesma, Bonne, Heymach, John V, Langmuir, Peter, Kennedy, Sarah J, Tada, Hiroomi, Johnson, Bruce E

Získat plný text Získat plný text Získat plný text

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease Autor Schroeder, Mark A., Khoury, H. Jean, Jagasia, Madan, Ali, Haris, Schiller, Gary J., Staser, Karl, Choi, Jaebok, Gehrs, Leah, Arbushites, Michael C., Yan, Ying, Langmuir, Peter, Srinivas, Nithya, Pratta, Michael, Perales, Miguel-Angel, Chen, Yi-Bin, Meyers, Gabrielle, DiPersio, John F.

Získat plný text Získat plný text Získat plný text

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 tri... Autor Han, MeiLan K, Antila, Martti, Ficker, Joachim H, Gordeev, Ivan, Guerreros, Alfredo, Bernus, Amparo Lopez, Roquilly, Antoine, Sifuentes-Osornio, José, Tabak, Fehmi, Teijeiro, Ricardo, Bandelli, Lorraine, Bonagura, Diane S, Shu, Xu, Felser, James M, Knorr, Barbara, Cao, Weihua, Langmuir, Peter, Lehmann, Thomas, Levine, Michael, Savic, Sinisa

Získat plný text Získat plný text Získat plný text